{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the confidence interval was not estimable because too few participants had events of loss of response (disease progression) or death.","groupId":"OG000","lowerLimit":"15.51","upperLimit":"NA","value":"53.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"Investigator assessment"},{"categories":[{"measurements":[{"comment":"The median and the upper limit of the confidence interval were not estimable because too few participants had events of loss of response (disease progression) or death.","groupId":"OG000","lowerLimit":"27.86","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"title":"CRC assessment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"Duration of response was defined as the time from the first assessment of complete response or partial response to the earlier of the date of first worsening assessment after response or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pemigatinib 13.5 milligrams (mg) was self-administered once daily (QD) as oral tablets on an intermittent dosing (ID) schedule or continuous dosing (CD) schedule. Participants started pemigatinib 13.5 mg on the ID schedule (i.e., 2 weeks on/1 week off) as per the initial Protocol and on the CD schedule in 21-day cycles following a Protocol amendment.","id":"OG000","title":"Pemigatinib 13.5 mg"}],"paramType":"MEDIAN","populationDescription":"Full Efficacy-Evaluable Population. Only participants with complete response or partial response were analyzed. Confidence intervals were calculated based on the exact method for binomial distribution.","reportingStatus":"POSTED","timeFrame":"up to 2513 days (120 21-day treatment cycles)","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}